Clinical utility of the PLAC® Activity Test

The PLAC® Test for Lp-PLA2 Activity (PLAC Activity) improves primary prevention of CHD events

• The only Lp-PLA2 blood test cleared by the FDA as an aid in predicting risk for coronary heart disease (CHD) in patients with no prior history of cardiovascular events
• Measures the activity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory marker that is critical in the formation of rupture-prone plaque1
• Identifies patients that may require a greater degree of risk mitigation

The PLAC Activity Test identifies risk in patients independent of other risk factors

• In a large cohort of patients hospitalized with coronary artery disease, nearly 50% had admission LDL levels <100 mg/dL2
• The PLAC Activity Test provides prognostic value independent of standard lipid profile testing, other biomarkers, and risk factors3

The PLAC Activity Test is easy to use and is supported by robust clinical study data

• The Lp-PLA2 REGARDS substudy prospectively validated a 225 nmol/min/mL cut point in 4,598 case-matched patients
• A PLAC Activity Test result above 225 identifies patients at increased risk for CHD events across patient type and population4
• The greater the Lp-PLA2 activity, the greater the risk for fatal and nonfatal CHD events5

Lp-PLA2 testing is well studied and published in peer-reviewed scientific literature and is recognized in the American Heart Association Guidelines, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice, and European Guidelines on CVD Prevention in Clinical Practices. See guidelines and recommendations.

---

Please also visit our Clinical Knowledge Portal to discover a suite of reference tools, clinical support materials, and expert perspectives on CHD risk, Lp-PLA2, and PLAC Activity testing.

---

• 
  Order Test
• 
  Visit Clinical Knowledge Portal
• 
  Get Additional Updates